Diabetes, Vol 41, Issue 11 1453-1463, Copyright © 1992 by American Diabetes Association
Hyperglycemia markedly enhances skeletal muscle glycogen synthase activity in diabetic, but not in normal conscious rats
S Farrace and L Rossetti
Department of Medicine, University of Texas Health Science Center, San Antonio.
Both hyperinsulinemia and hyperglycemia stimulate skeletal muscle glucose
uptake. However, the intracellular metabolic fate of the phosphorylated
glucose may be different when the prevalent stimulus for glucose uptake is
hyperinsulinemia or hyperglycemia. To define the impact of hyperglycemia on
the intracellular glucose disposal, we studied control and diabetic
conscious rats under four experimental conditions: 1) basal insulin and
basal glucose; 2) basal insulin and high glucose; 3) high insulin and basal
glucose; and 4) high insulin and high glucose. Under both basal insulin
(130 pM) and high insulin (2500 pM), hyperglycemia (15 mM) increased
glucose uptake and muscle and liver glycogen synthesis similarly in control
and diabetic rats. Hyperglycemia resulted in a more significant decline in
the muscle G-6-P concentration in diabetic rats than in control rats,
suggesting activation of intracellular glucose metabolism. The diabetic
skeletal muscle glycogen synthase was severely resistant to insulin
stimulation compared with control (FV0.1 = 0.31 +/- 0.04 vs. 0.49 +/- 0.03;
Km = 0.19 +/- 0.05 vs. 0.10 +/- 0.01 mM; P < 0.01), but it was markedly
responsive to glucose stimulation under both basal (FV0.1 = 0.38 +/- 0.03
vs. 0.21 +/- 0.03; Km = 0.10 +/- 0.01 vs. 0.35 +/- 0.08 mM) and high
insulin (FV0.1 = 0.65 +/- 0.07 vs. 0.31 +/- 0.04; Km = 0.11 +/- 0.02 vs.
0.19 +/- 0.05 mM). By contrast, in control rats, hyperglycemia did not
exert any stimulatory effect on skeletal muscle glycogen synthase. Thus,
some metabolic alteration associated with the diabetic state renders the
skeletal muscle glycogen synthase selectively responsive to glucose
stimulation. This may represent a compensatory mechanism for the severe
impairment in insulin's activation of this enzyme in diabetes.